BFSG LLC’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BFSG LLC’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-49	Closed	-$2.88K	–	714
2023 Q4	$2.88K	Buy	+49	New	+$2.75K	﹤0.01%	528
2021 Q1	–	Sell	-2,916	Closed	-$640K	–	220
2020 Q4	$640K	Buy	2,916 +151	+5%	+$32.6K	0.11%	154
2020 Q3	$459K	Buy	2,765 +28	+1%	+$3.83K	0.09%	151
2020 Q2	$312K	Buy	+2,737	New	+$265K	0.07%	150

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BFSG LLC's MRTX Position: Q1 2024 in Review

BFSG LLC sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 49 shares — an estimated $2.88K sold.

BFSG LLC first reported a position in MRTX in Q2 2020 and held it in 4 quarters. The position peaked at $640K in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

BFSG LLC reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
BFSG LLC sold 49 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.88K.
BFSG LLC first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
BFSG LLC's Mirati Therapeutics, Inc. Common Stock position peaked at $640K in Q4 2020.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on BFSG LLC's 13F filing for Q1 2024, filed 23 Apr 2024.